Conversely, treatment of cancer cells with 1 ng of recombinant IL-6 mimicked CAF chemoprotection, although less efficiently than whole CAF-CM, since a residual fraction of PARP remained cleaved (Fig6F). The gene discussed is IL6; the disease is cancer.